ADC Therapeutics
company
About
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
- 251 - 500
Details
- Last Funding Type
- Series E
- Last Funding Money Raised
- Fr76M
- Industries
- Biopharma,Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 2011
- Number Of Employee
- 251 - 500
- Operating Status
- Active
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
Fr76M $385M
ADC Therapeutics has raised a total of
Fr76M $385M
in funding over 2 rounds. Their latest funding was raised on
Jun 12, 2019 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 12, 2019 | Series E | Fr76M | 1 | — | — | Detail |
| Oct 23, 2017 | Series E | $200M | 1 | — | — | Detail |
| Oct 27, 2016 | Series D | $105M | 1 | — | — | Detail |
| Sep 2, 2015 | Series C | $80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
ADC Therapeutics is funded by 1 investors.
AstraZeneca
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
AstraZeneca
|
— | Series E |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
